Atorvastatin does not exhibit antiviral activity against HCV at conventional doses: A pilot clinical trial

Hepatology

Volumn 45, Issue 4, 2007, Pages 895-898

  O'Leary, Jacqueline G ^a   Chan, Jessica L ^a   McMahon, Cory M ^a   Chung, Raymond T ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ATORVASTATIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INTERFERON; LOW DENSITY LIPOPROTEIN; VIRUS RNA;

ADULT; ANTIVIRAL ACTIVITY; ARTICLE; BODY MASS; CHOLESTEROL DIET; CHOLESTEROL SYNTHESIS; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DEMOGRAPHY; DRUG EFFECT; DRUG WITHDRAWAL; FEMALE; FOLLOW UP; GENOTYPE; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; LIVER TOXICITY; MYALGIA; PRIORITY JOURNAL; VIRUS REPLICATION;

ADULT; AGED; FEMALE; HEPACIVIRUS; HEPATITIS C, CHRONIC; HEPTANOIC ACIDS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MALE; MIDDLE AGED; PILOT PROJECTS; PYRROLES; VIRUS REPLICATION;

EID: 34247378117     PISSN: 02709139     EISSN: None     Source Type: Journal    
DOI: 10.1002/hep.21554     Document Type: Article

References (12)

1. Aizaki H, Lee KJ, Sung VM, Ishiko H, Lai MM. Characterization of the hepatitis C virus RNA replication complex associated with lipid rafts. Virology 2004;324:450-461.
2. Ye J, Wang C, Sumpter R Jr, Brown MS, Goldstein JL, Gale M Jr. Disruption of hepatitis C virus RNA replication through inhibition of host protein geranylgeranylation. Proc Natl Acad Sci U S A 2003;100:15865-15870.
3. Kapadia SB, Chisari FV. Hepatitis C virus RNA replication is regulated by host geranylgeranylation and fatty acids. Proc Natl Acad Sci USA 2005; 102:2561-2566.
4. Jarmay K, Karacsony G, Nagy A, Schaff Z. Changes in lipid metabolism in chronic hepatitis C. World J Gastroenterol 2005;11:6422-6428.
5. Maggi G, Bottelli R, Gola D, Perricone G, Posca M, Zavaglia C, et al. Serum cholesterol and chronic hepatitis C. Ital J Gastroenterol 1996;28: 436-440.
6. Siagris D, Christofidou M, Theocharis GJ, Pagoni N, Papadimitriou C, Lekkou A, et al. Serum lipid pattetn in chronic hepatitis C: histological and virological correlarions. J Viral Hepat 2006;13:56-61.
7. Hamamoto S, Uchida Y, Wada T, Moritani M, Sato S, Hamamoto N, et al. Changes in serum lipid concentrations in patients with chronic hepatitis C virus positive hepatitis responsive or non-responsive to interferon therapy. J Gastroenterol Hepatol 2005;20:204-208.
8. Ikeda M, Abe K, Yamada M, Dansako H, Naka K, Kato N. Different anti-HCV profiles of statins and their potential for combination therapy with interferon. HEPATOLOGY 2006;44:117-125.
9. Kim SS, Peng LF, Lin W, et al. A cell-based, high-throughput screen for small molecule regulators of hepatitis C virus replication. Gastroenterology 2007;132:311-320.
10. Backman JT, Luurila H, Neuvonen M, Neuvonen PJ. Rifampin markedly decreases and gemfibrozil increases the plasma concentrations of atorvastatin and its metabolites. Clin Pharmacol Ther 2005;78:154-167.
11. Gopal K, Johnson JC, Gopal S, Walfish A, Bang CT, Suwandhi P, et al. Correlation between beta-lipoprotein levels and outcome of hepatitis C treatment. HEPATOLOGY 2006;44:335-340.
12. Fujita N, Kaito M, Kai M, Sugimoto R, Tanaka H, Horike S, et al. Effects of bezafibrate in patients with chronic hepatitis C virus infection: combination with interferon and ribavirin. J Viral Hepat 2006;13:441-448.